- Home
- BFST vs SLS Comparison
BFST vs SLS Comparison
Compare BFST & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | SLS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 924.5M |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BFST | SLS |
|---|---|---|
| Price | $28.48 | $8.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $32.75 | $10.00 |
| AVG Volume (30 Days) | 151.2K | ★ 11.1M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 50.00 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $10,704,000.00 | N/A |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $5.02 | $110.98 |
| P/E Ratio | $41.84 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $22.56 | $1.39 |
| 52 Week High | $30.32 | $9.51 |
Technical Indicators
Market Signals| Indicator | BFST | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 55.18 |
| Support Level | $26.73 | $3.72 |
| Resistance Level | $29.44 | $9.51 |
| Average True Range (ATR) | 0.55 | 0.89 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 86.32 | 43.80 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.